First implant of InControl's Metrix 3020:
This article was originally published in Clinica
InControl's Metrix 3020 atrial defibrillator has been implanted for the first time at the Universitair Ziekenhuis Ghent in Belgium. The defibrillator incorporates a waveform which allows the delivery of up to six Joules of energy as compared with three Joules for the company's Metrix 3000 defibrillator. The Metrix 3020 is approved for clinical investigation in Belgium but is awaiting regulatory clearance in other European countries and the US (see Clinica No 699, p 18).
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.